Nat Commun: The immune checkpoint scoring system improves the accuracy of gastric cancer prognosmation assessment

In recent years, more and more oncology research has focused on anti-tumor immune response, which may become a major sign of cancer immunotherapy.
that although significant progress has been made in immunotherapy, a large number of patients are still unable to benefit, which may be related to the immunosuppressive environment of tumors.
immune checkpoints expressed on tumor cells play a vital role in protecting tumor cells from host immune responses, especially local immunity.
this immunosuppressive tumor microencase can help the tumor evade immune identification, which in turn promotes tumor proliferation, local development and systemic diffusion.
previous studies have shown a significant correlation between tumor-immersive lymphocyte (TILs) status and prognostic nutrition index (PNI) scores, an indicator of nutritional status and systemic immunity.
patients with higher PNI scores were more likely to have strong lymphocyte immersion in tumor tissue than patients with lower scores.
, however, it is not clear whether a higher PNI score will benefit patients with immunosuppressive tumor micro-environments.
is a valuable prognossis biological marker for patients across different cancer types, using ISSGC's Prognossis Value Immune Checkpoint.
, however, the diversity of immune checkpoints makes it worrying to predict the accuracy of clinical outcomes based only on a single immunization checkpoint.
, a model is needed to integrate multiple immune checkpoints.
In this study, the researchers used the LASSO method (minimum absolute contraction and choice of arithmetic method) to establish an integrated immunometric scoring system (ISSGC) based on six immunosuppressive lipenes (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44, and CD155) to improve the accuracy of patient prognostic prediction and to provide alternative treatment strategies for assisted chemotherapy for stomach cancer (GC).
results of PNI scores and ISSGC show that ISSGC is an independent prognostic factor and a supplement to TNM phases in GC patients, which can improve the accuracy of patient prognostic prediction.
addition, it can distinguish between patients with better prognostic GC and 10th-of-life patients with higher prognostic nutrition index.
, ISSGC can choose beneficial complementary chemotherapy strategies for GC patients independently of patients' TNM stages, MSI status, and EBV status.
, the results provide a way to study the prognosmation effects of local immunosuppression by analyzing the combination of immunosuppression checkpoints.
the association of ISSGC and TNM phases can improve the accuracy of prognosmation.
addition, ISSGC assisted in assessing the benefits of chemotherapy.
。